For example, palbociclib showed in combination with letrozole [87] and in combination with fulvestrant [88] increased progression-free survival (PFS) of hormonal receptor positive Her2- breast cancer patients compared to control patient groups. This evidence concerns the gene ERBB2 and breast cancer.